Krystal Biotech, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Krystal Biotech, Inc. (KRYS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $30.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-03
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $30.40M, a 1420.00% increase year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $32.10M, a 2192.86% increase year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $27.30M, a 493.48% increase year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $4.80M, a 18.64% decline year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $35.40M, a 35.40% decline from fiscal 2024.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $54.80M, a 25.11% increase from fiscal 2023.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $43.80M, a 1410.34% increase from fiscal 2022.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $2.90M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $30.40M 10-Q · filed 2026-08-03 | $62.50M 10-Q · filed 2026-08-03 | $89.80M derived: sum of 3 quarters · filed 2026-08-03 | $94.60M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2026-03-31 | $32.10M 10-Q · filed 2026-05-04 | $59.40M derived: sum of 2 quarters · filed 2026-05-04 | $64.20M derived: sum of 3 quarters · filed 2026-05-04 | $66.20M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-12-31 | $27.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $32.10M derived: sum of 2 quarters · filed 2026-02-17 | $34.10M derived: sum of 3 quarters · filed 2026-08-03 | $35.40M 10-K · filed 2026-02-17 | ||||
| 2025-09-30 | $4.80M 10-Q · filed 2025-11-03 | $6.80M derived: sum of 2 quarters · filed 2026-08-03 | $8.10M 10-Q · filed 2025-11-03 | $12.80M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-06-30 | $2.00M 10-Q · filed 2026-08-03 | $3.40M 10-Q · filed 2026-08-03 | $8.00M derived: sum of 3 quarters · filed 2026-08-03 | $13.90M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-03-31 | $1.40M 10-Q · filed 2026-05-04 | $6.00M derived: sum of 2 quarters · filed 2026-05-04 | $11.90M derived: sum of 3 quarters · filed 2026-05-04 | $31.70M derived: sum of 4 quarters · filed 2026-05-04 | ||||
| 2024-12-31 | $4.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $10.50M derived: sum of 2 quarters · filed 2026-02-17 | $30.30M derived: sum of 3 quarters · filed 2026-02-17 | $54.80M 10-K · filed 2026-02-17 | ||||
| 2024-09-30 | $5.90M 10-Q · filed 2025-11-03 | $25.70M derived: sum of 2 quarters · filed 2025-11-03 | $50.20M 10-Q · filed 2025-11-03 | $52.60M derived: sum of 4 quarters · filed 2026-02-17 | ||||
| 2024-06-30 | $19.80M 10-Q · filed 2025-08-04 | $44.30M 10-Q · filed 2025-08-04 | $46.70M derived: sum of 3 quarters · filed 2026-02-17 | $60.20M derived: sum of 4 quarters · filed 2026-02-17 | ||||
| 2024-03-31 | $24.50M 10-Q · filed 2025-05-06 | $26.90M derived: sum of 2 quarters · filed 2026-02-17 | $40.40M derived: sum of 3 quarters · filed 2026-02-17 | $67.10M derived: sum of 4 quarters · filed 2026-02-17 | ||||
| 2023-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $15.90M derived: sum of 2 quarters · filed 2026-02-17 | $42.60M derived: sum of 3 quarters · filed 2026-02-17 | $43.80M 10-K · filed 2026-02-17 | ||||
| 2023-09-30 | $13.50M 10-Q · filed 2024-11-04 | $40.20M derived: sum of 2 quarters · filed 2024-11-04 | $41.40M 10-Q · filed 2024-11-04 | $42.10M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-06-30 | $26.70M 10-Q · filed 2024-08-05 | $27.90M 10-Q · filed 2024-08-05 | $28.60M derived: sum of 3 quarters · filed 2025-02-19 | $29.90M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-03-31 | $1.10M 10-Q · filed 2024-05-06 | $1.90M derived: sum of 2 quarters · filed 2025-02-19 | $3.20M derived: sum of 3 quarters · filed 2025-02-19 | $3.90M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2022-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $2.10M derived: sum of 2 quarters · filed 2025-02-19 | $2.80M derived: sum of 3 quarters · filed 2025-02-19 | $2.90M 10-K · filed 2025-02-19 | ||||
| 2022-09-30 | $1.30M 10-Q · filed 2023-11-06 | $2.00M derived: sum of 2 quarters · filed 2023-11-06 | $2.10M 10-Q · filed 2023-11-06 | |||||
| 2022-06-30 | $704.00K 10-Q · filed 2023-08-07 | $739.00K 10-Q · filed 2023-08-07 | ||||||
| 2022-03-31 | $36.00K 10-Q · filed 2023-05-08 | |||||||
| 2021-09-30 | $64.00K 10-Q · filed 2022-11-07 | $348.00K 10-Q · filed 2021-11-08 | $128.00K derived: sum of 2 quarters · filed 2022-11-07 | $872.00K 10-Q · filed 2022-11-07 | $1.20M 10-Q · filed 2021-11-08 | $1.14M derived: sum of 4 quarters · filed 2022-11-07 | ||
| 2021-06-30 | $64.00K 10-Q · filed 2022-08-08 | $808.00K 10-Q · filed 2021-08-09 | $872.00K 10-Q · filed 2022-08-08 | $1.07M derived: sum of 3 quarters · filed 2022-08-08 | $2.77M derived: sum of 4 quarters · filed 2022-08-08 | |||
| 2021-03-31 | $808.00K 10-Q · filed 2022-05-09 | $1.01M derived: sum of 2 quarters · filed 2022-05-09 | $2.71M derived: sum of 3 quarters · filed 2022-05-09 | $3.36M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $1.90M derived: sum of 2 quarters · filed 2021-11-08 | $2.56M derived: sum of 3 quarters · filed 2021-11-08 | $3.10M 10-K · filed 2021-03-01 | ||||
| 2020-09-30 | $1.70M 10-Q · filed 2021-11-08 | $2.36M derived: sum of 2 quarters · filed 2021-11-08 | $2.90M 10-Q · filed 2021-11-08 | $5.42M 10-Q · filed 2020-11-09 | $5.08M derived: sum of 4 quarters · filed 2021-11-08 | |||
| 2020-06-30 | $656.00K 10-Q · filed 2021-08-09 | $1.20M 10-Q · filed 2021-08-09 | $3.70M 10-Q · filed 2020-08-07 | $3.38M derived: sum of 3 quarters · filed 2021-08-09 | $3.52M derived: sum of 4 quarters · filed 2021-08-09 | |||
| 2020-03-31 | $656.00K 10-Q · filed 2021-05-10 | $3.35M 10-Q · filed 2020-05-04 | $2.73M derived: sum of 2 quarters · filed 2021-05-10 | $2.86M derived: sum of 3 quarters · filed 2021-05-10 | $3.01M derived: sum of 4 quarters · filed 2021-05-10 | |||
| 2019-12-31 | $2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $2.21M derived: sum of 2 quarters · filed 2021-03-01 | $2.36M derived: sum of 3 quarters · filed 2021-03-01 | $2.80M 10-K · filed 2021-03-01 | $3.78M 10-K · filed 2020-03-10 | |||
| 2019-09-30 | $133.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $286.00K derived: sum of 2 quarters · filed 2019-11-04 | $728.00K 10-Q · filed 2019-11-04 | |||||
| 2019-06-30 | $153.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $595.00K 10-Q · filed 2019-08-05 | ||||||
| 2019-03-31 | $442.00K 10-Q · filed 2019-05-07 | |||||||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $35.00K derived: sum of 2 quarters · filed 2018-11-05 | $53.00K 10-Q · filed 2018-11-05 | |||||
| 2018-06-30 | $35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $53.00K 10-Q · filed 2018-08-06 | ||||||
| 2018-03-31 | $18.00K 10-Q · filed 2018-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |